Related Experiment Videos
Systemic embolism in chronic left ventricular aneurysm: incidence and the role of anticoagulation
Insights
Systemic embolism is rare in patients with chronic left ventricular aneurysm. This study found the low incidence does not support routine long-term oral anticoagulation therapy for these patients.
Area of Science:
- Cardiology
- Vascular Medicine
- Thrombosis Research
Background:
- Chronic left ventricular aneurysm (LV aneurysm) poses a risk for systemic embolism, but optimal prevention strategies remain debated.
- Oral anticoagulation is a potential method for preventing embolic events in high-risk cardiovascular conditions.
Purpose of the Study:
- To investigate the incidence of systemic embolism in patients with chronic left ventricular aneurysm.
- To evaluate the effectiveness of oral anticoagulation in preventing embolic events in this patient population.
Main Methods:
- Retrospective analysis of 76 patients with angiographically defined left ventricular aneurysm between 1971 and 1979.
- Comparison of embolic event incidence in patients on oral anticoagulant therapy versus those not receiving it.
- Follow-up data analyzed for patient-years and survival rates.
Main Results:
- Only one non-anticoagulated patient experienced a clinical embolic event (0.35 per 100 patient-years).
- Survival rates at 3 and 5 years were 75% and 61%, respectively.
- The study observed a very low incidence of systemic emboli in patients with chronic LV aneurysm.
Conclusions:
- The extremely low incidence of systemic emboli in patients with chronic left ventricular aneurysm, in the absence of other risk factors, does not warrant routine long-term oral anticoagulant therapy.
- Further research may explore specific patient subgroups who might benefit from anticoagulation.
- Current findings suggest a re-evaluation of anticoagulation guidelines for this condition.
Abstract:
The incidence and prevention of systemic embolism in patients with chronic left ventricular aneurysm have been controversial. This retrospective study investigated the incidence of clinically evident embolic events and the effect of oral anticoagulation in patients with unequivocal angiographically defined left ventricular aneurysm. Between 1971 and 1979, 76 patients met the ventriculographic criteria and received initial medical management. The median interval from myocardial infarction to ventriculography was 11 months (range 1 month to 16 years) and subsequent median follow-up time was 5 years. Twenty patients receiving anticoagulant therapy were followed up for a total of 40 patient-years and 69 patients not on anticoagulant therapy were followed up for a total of 288 patient-years; 13 patients were included in both subsets. Twenty-eight patients died during follow-up and the 3 and 5 year survival rates were 75 and 61%, respectively. Only one patient not receiving anticoagulant therapy had a clinical embolic event, resulting in an incidence of 0.35 per 100 patient-years. Therefore, in the absence of other predisposing conditions, the extremely low incidence of systemic emboli in these patients with chronic (first documented at least 1 month after myocardial infarction) left ventricular aneurysm does not justify the use of long-term oral anticoagulant therapy.